Closure of venous that remained patent from fetal duration

Prophylactic intravenous Indomethacin effect in decreasing symptomatic Patent Ductus Arteriosus (PDA) and assisted ventilation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107117010N1

Enrollment

Registered

2011-10-17

Start date

2011-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent Ductus Arteriosus. Persistent ductus arteriosus

Interventions

Intervention 1: Intervention group: Intravenous (IV) indomethacin at 2-12 first hours with dosage of 0.2mg\kg and then 0.1mg/kg after 24 and 48 hours. Intervention 2: Control group: without any inter

Treatment - Drugs

Intervention group: Intravenous (IV) indomethacin at 2-12 first hours with dosage of 0.2mg\kg and then 0.1mg/kg after 24 and 48 hours

Control group: without any intervention

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: birth in Alzehra hospital and gestational age equal or lower than 32 week; birth weight equal or between 800-1500g. Exclusion criteria: congenital anomaly; severe asphyxia; thrombocytopenia(plt1.8mg\dl; bleeding tendency; mother consumption of indomethacine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decreasing symptomatic PDA (severity of PDA). Timepoint: 4 days. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Decreasing assisted ventilation. Timepoint: First 14 days of birth. Method of measurement: Visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahmood Samadi

Tabriz University of Medical Science, Pediatric Department

Samadima@tbzmed.ac.ir , Dr_samadi_pedcard@yahoo.com+98 41 1526 2280

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026